Bio-Techne (TECH) Cash & Equivalents (2009 - 2026)

Bio-Techne's Cash & Equivalents history runs 18 years deep, the most recent figure standing at $209.8 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 49.16% year-over-year to $209.8 million; the TTM figure through Mar 2026 stood at $209.8 million (up 49.16% YoY), while the FY2025 annual figure was $162.2 million, up 6.85% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $209.8 million, up from $172.9 million in the prior quarter.
• The five-year high for Cash & Equivalents was $209.8 million in Q1 2026, with the low at $127.3 million in Q1 2023.
• The 5-year median for Cash & Equivalents is $162.2 million (2025), against an average of $161.0 million.
• The sharpest annual moves came in 2025 and 2026: Cash & Equivalents fell 22.7% in 2025, then jumped 49.16% in 2026.
• Bio-Techne's Cash & Equivalents stood at $164.7 million in 2022, then dropped by 20.98% to $130.1 million in 2023, then jumped by 36.44% to $177.5 million in 2024, then slipped by 2.63% to $172.9 million in 2025, then rose by 21.37% to $209.8 million in 2026.
• Business Quant data shows TECH's Cash & Equivalents at $209.8 million in Q1 2026, $172.9 million in Q4 2025, and $145.0 million in Q3 2025.